Coherus BioSciences Reaches Clinical and Regulatory Milestones for Udenyca and CHS-201
October 6th 2021
ArticlePositive findings for Coherus BioSciences' ranibizumab candidate (CHS-201) were presented at the Scientific Meeting of the Retina Society, and the company said equivalence end points were met for an on-body injector version of Udenyca (pegfilgrastim).